LyphoSign completes early-stage LS104 study
Canadian biopharmaceutical company LymphoSign says it has completed preclinical testing of its developmental kinase inhibitor LS104, and adds that it intends to begin human trials of the drug in the treatment of acute myeloid leukemia and other blood cancers in the near future.
The preclinical work has suggested that the compound confers a significant survival advantage in animal myeloid leukemia models. Helmut Thomas, the company's vice president, said that the drug has also shown efficacy in cultured leukemia, myeloma and lymphoma cells in vitro.
LymphoSign says it is preparing a Clinical Trial Application for regulatory authorities in Canada and Europe and expects to submit an Investigational New Drug application to the US Food and Drug Administration in 2007.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze